Atreca, Inc. Profile Avatar - Palmy Investing

Atreca, Inc.

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and t…

Biotechnology
US, South San Francisco [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of BCEL's Analysis
CIK: 1532346 CUSIP: 04965G109 ISIN: US04965G1094 LEI: - UEI: -
Secondary Listings
BCEL has no secondary listings inside our databases.